|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tennant DA, Durán RV and Gottlieb E:
Targeting metabolic transformation for cancer therapy. Nat Rev
Cancer. 10:267–277. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heiden MG Vander, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wise DR and Thompson CB: Glutamine
addiction: A new therapeutic target in cancer. Trends Biochem Sci.
35:427–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Catchpole G, Platzer A, Weikert C,
Kempkensteffen C, Johannsen M, Krause H, Jung K, Miller K,
Willmitzer L, Selbig J and Weikert S: Metabolic profiling reveals
key metabolic features of renal cell carcinoma. J Cell Mol Med.
15:109–118. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dang CV: Links between metabolism and
cancer. Genes Dev. 26:877–890. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deblois G and Giguère V: Oestrogen-related
receptors in breast cancer: Control of cellular metabolism and
beyond. Nat Rev Cancer. 13:27–36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dang CV, Le A and Gao P: MYC-induced
cancer cell energy metabolism and therapeutic opportunities. Clin
Cancer Res. 15:6479–6483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jones RG and Thompson CB: Tumor
suppressors and cell metabolism: A recipe for cancer growth. Genes
Dev. 23:537–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qing G, Li B, Vu A, Skuli N, Walton ZE,
Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM, et al: ATF4
regulates MYC-mediated neuroblastoma cell death upon glutamine
deprivation. Cancer Cell. 22:631–644. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGivan JD and Bungard CI: The transport
of glutamine into mammalian cells. Front Biosci. 12:874–882. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren P, Yue M, Xiao D, Xiu R, Gan L, Liu H
and Qing G: ATF4 and N-Myc coordinate glutamine metabolism in
MYCN-amplified neuroblastoma cells through ASCT2 activation. J
Pathol. 235:90–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Q, Beaumont KA, Otte NJ, Font J,
Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM,
Jormakka M, et al: Targeting glutamine transport to suppress
melanoma cell growth. Int J Cancer. 135:1060–1071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frigerio F, Casimir M, Carobbio S and
Maechler P: Tissue specificity of mitochondrial glutamate pathways
and the control of metabolic homeostasis. Biochim Biophys Acta.
1777:965–972. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li M, Li C, Allen A, Stanley CA and Smith
TJ: The structure and allosteric regulation of mammalian glutamate
dehydrogenase. Arch Biochem Biophys. 519:69–80. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wise DR, DeBerardinis RJ, Mancuso A, Sayed
N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon
SB and Thompson CB: Myc regulates a transcriptional program that
stimulates mitochondrial glutaminolysis and leads to glutamine
addiction. Proc Natl Acad Sci USA. 105:pp. 18782–18787. 2008;
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boulkroun S, Fay M, Zennaro MC, Escoubet
B, Jaisser F, Blot-Chabaud M, Farman N and Courtois-Coutry N:
Characterization of rat NDRG2 (N-Myc downstream regulated gene 2),
a novel early mineralocorticoid-specific induced gene. J Biol Chem.
277:31506–31515. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu
X, Au WS, Wang J, Li F, Ji S, et al: N-Myc downstream-regulated
gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J
Cancer. 106:342–347. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lusis EA, Watson MA, Chicoine MR, Lyman M,
Roerig P, Reifenberger G, Gutmann DH and Perry A: Integrative
genomic analysis identifies NDRG2 as a candidate tumor suppressor
gene frequently inactivated in clinically aggressive meningioma.
Cancer Res. 65:7121–7126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Phillips HS, Kharbanda S, Chen R, Forrest
WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et
al: Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in
neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma J, Jin H, Wang H, Yuan J, Bao T, Jiang
X, Zhang W, Zhao H and Yao L: Expression of NDRG2 in clear cell
renal cell carcinoma. Biol Pharm Bull. 31:1316–1320. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Faraji SN, Mojtahedi Z, Ghalamfarsa G and
Takhshid MA: N-myc downstream regulated gene 2 overexpression
reduces matrix metalloproteinase-2 and −9 activities and cell
invasion of A549 lung cancer cell line in vitro. Iran J Basic Med
Sci. 18:773–779. 2015.PubMed/NCBI
|
|
27
|
Xu X, Li J, Sun X, Guo Y, Chu D, Wei L, Li
X, Yang G, Liu X, Yao L, et al: Tumor suppressor NDRG2 inhibits
glycolysis and glutaminolysis in colorectal cancer cells by
repressing c-Myc expression. Oncotarget. 6:26161–26176. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shim H, Dolde C, Lewis BC, Wu CS, Dang G,
Jungmann RA, Dalla-Favera R and Dang CV: c-Myc transactivation of
LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad
Sci USA. 94:pp. 6658–6663. 1997; View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen JQ and Russo J: Dysregulation of
glucose transport, glycolysis, TCA cycle and glutaminolysis by
oncogenes and tumor suppressors in cancer cells. Biochim Biophys
Acta. 1826:370–384. 2012.PubMed/NCBI
|
|
30
|
Kim JW, Gao P, Liu YC, Semenza GL and Dang
CV: Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively
induce vascular endothelial growth factor and metabolic switches
hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol.
27:7381–7393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pérez-Escuredo J, Dadhich RK, Dhup S,
Cacace A, Van Hée VF, De Saedeleer CJ, Sboarina M, Rodriguez F,
Fontenille MJ, Brisson L, et al: Lactate promotes glutamine uptake
and metabolism in oxidative cancer cells. Cell Cycle. 15:72–83.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma JJ, Liao CG, Jiang X, Zhao HD, Yao LB
and Bao TY: NDRG2 suppresses the proliferation of clear cell renal
cell carcinoma cell A-498. J Exp Clin Cancer Res. 29:1032010.
View Article : Google Scholar : PubMed/NCBI
|
